GB697351A - Improved process for the manufacture of nerve sedatives - Google Patents
Improved process for the manufacture of nerve sedativesInfo
- Publication number
- GB697351A GB697351A GB6474/51A GB647451A GB697351A GB 697351 A GB697351 A GB 697351A GB 6474/51 A GB6474/51 A GB 6474/51A GB 647451 A GB647451 A GB 647451A GB 697351 A GB697351 A GB 697351A
- Authority
- GB
- United Kingdom
- Prior art keywords
- sedative
- tissues
- dispersion
- saline solution
- animals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A sedative for all the peripheral nerves is prepared by inoculating or infecting organs or tissues of animals such as cows or rabbits with cowpox, removing the organs or tissues 3 to 10 days after inoculation or infection, dispersing them in an aqueous medium, completely removing protein ingredients from the dispersion, and recovering the sedative, which contains no virus protein or lipoid, from the liquid so obtained. The aqueous medium is physiological saline solution, water, glycerin water, or a mixture thereof, containing carbolic acid. In the example, a portion of the testicles or skins of animals is removed 4-5 days after inoculation, well-ground and dispersed in a mixture of physiological saline solution, glycerin and carbolic acid. The dispersion is alternatively frozen at -5 to -10 DEG C. and thawed at 15-20 DEG C., allowed to stand, the supernatant liquid decanted and proteins removed in stages by (a) heating to 100 DEG C. for 1 hour (b) adjusting pH to 5 by the addition of hydrochloric acid and (c) filtering through asbestos treated with sodium silicate and magnesium sulphate. The filtrate from (c) is treated with kaolin at pH 4.5-4.7. The absorbate containing the virus and sedative is eluted with N/24-N/26 aqueous ammonia and filtered. The filtrate is adjusted to pH 7.4-7.8 with N/1 acetic acid, concentrated in vacuo, and the sedative precipitated by the addition of a water-miscible organic solvent e.g. acetone or ethylalcohol. The effective material can be isolated by cataphoresis of the clear liquid obtained after heating and freezing a dispersion of the tissues in saline solution. Active material may also be isolated from urine of infected animals or from a cowpox inoculated hatching egg.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP697351X | 1951-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB697351A true GB697351A (en) | 1953-09-23 |
Family
ID=13411354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB6474/51A Expired GB697351A (en) | 1951-01-16 | 1951-03-19 | Improved process for the manufacture of nerve sedatives |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB697351A (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5534509A (en) * | 1993-03-19 | 1996-07-09 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition regulating function of a living body |
US5560935A (en) * | 1993-09-28 | 1996-10-01 | Nippon Zoki Pharmaceutical Co., Ltd. | Physiologically active substances extracted from activated tissues |
US5599683A (en) * | 1993-08-06 | 1997-02-04 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for measuring production activity of test substance towards FXIIa |
US5648228A (en) * | 1993-08-06 | 1997-07-15 | Nippon Zoki Pharmaceutical Co., Ltd. | Measuring activity toward production of activated blood coagulation factor XII, plasma kallikrein or bradykinin using reconstituted kallikrein-kinin system |
US6051613A (en) * | 1997-01-08 | 2000-04-18 | Nippon Zoki Pharmaceutical Co., Ltd. | Nitrogen monoxide production suppressor |
US6165515A (en) * | 1997-09-12 | 2000-12-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for treatment of osteoporosis |
US6365192B1 (en) | 1999-04-15 | 2002-04-02 | Nippon Zoki Pharmaceutical Co., Ltd. | Bioactivating substance |
US6541041B1 (en) | 1997-11-28 | 2003-04-01 | Nippon Zoki Pharmaceutical Co., Ltd. | Crude drug extracts, and methods for making and standardizing same |
US6726932B2 (en) | 2000-02-18 | 2004-04-27 | Nippon Zoki Pharmaceutical Co., Ltd. | Fatty acid-containing composition |
US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
US8293280B2 (en) | 2004-12-17 | 2012-10-23 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for treatment of HIV infection |
US8568789B2 (en) | 2004-12-01 | 2013-10-29 | Nippon Zoki Pharmaceutical Co., Ltd. | Dried product and a process for manufacturing the product |
US9884077B2 (en) | 2013-04-30 | 2018-02-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Extract and preparation containing said extract |
-
1951
- 1951-03-19 GB GB6474/51A patent/GB697351A/en not_active Expired
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5658896A (en) * | 1993-03-19 | 1997-08-19 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition regulating function of a living body |
US5807951A (en) * | 1993-03-19 | 1998-09-15 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition regulating function of a living body |
US5534509A (en) * | 1993-03-19 | 1996-07-09 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition regulating function of a living body |
US5599683A (en) * | 1993-08-06 | 1997-02-04 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for measuring production activity of test substance towards FXIIa |
US5648228A (en) * | 1993-08-06 | 1997-07-15 | Nippon Zoki Pharmaceutical Co., Ltd. | Measuring activity toward production of activated blood coagulation factor XII, plasma kallikrein or bradykinin using reconstituted kallikrein-kinin system |
US5560935A (en) * | 1993-09-28 | 1996-10-01 | Nippon Zoki Pharmaceutical Co., Ltd. | Physiologically active substances extracted from activated tissues |
US6051613A (en) * | 1997-01-08 | 2000-04-18 | Nippon Zoki Pharmaceutical Co., Ltd. | Nitrogen monoxide production suppressor |
US6165515A (en) * | 1997-09-12 | 2000-12-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for treatment of osteoporosis |
US6576241B2 (en) | 1997-11-28 | 2003-06-10 | Nippon Zoki Pharmaceutical Co., Ltd. | Crude drug extracts, and methods for making and standardizing same |
US6541041B1 (en) | 1997-11-28 | 2003-04-01 | Nippon Zoki Pharmaceutical Co., Ltd. | Crude drug extracts, and methods for making and standardizing same |
US6365192B1 (en) | 1999-04-15 | 2002-04-02 | Nippon Zoki Pharmaceutical Co., Ltd. | Bioactivating substance |
US6726932B2 (en) | 2000-02-18 | 2004-04-27 | Nippon Zoki Pharmaceutical Co., Ltd. | Fatty acid-containing composition |
US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
US8568789B2 (en) | 2004-12-01 | 2013-10-29 | Nippon Zoki Pharmaceutical Co., Ltd. | Dried product and a process for manufacturing the product |
US8293280B2 (en) | 2004-12-17 | 2012-10-23 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for treatment of HIV infection |
US9884077B2 (en) | 2013-04-30 | 2018-02-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Extract and preparation containing said extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vogel et al. | Adsorption-hemagglutination test for influenza virus in monkey kidney tissue culture | |
US3396081A (en) | Hyaluronic acid preparation and method of producing same | |
GB697351A (en) | Improved process for the manufacture of nerve sedatives | |
Underdahl et al. | Cultivation in tissue-culture of cytopathogenic agent from bovine mucosal disease. | |
Rogers et al. | The physiology of the second ecdysis of parasitic nematodes | |
Bremner et al. | Acetylcholinesterase secretion by parasitic nematodes—III. Oesophagostomum spp. | |
Carrel | Essential characteristics of a malignant cell | |
Lack | Spherule Formation and Endosporulation of the Fungus Coccidioides in vitro. | |
Beckett et al. | Some histochemical observations on human dystrophic muscle | |
Findlay | A note on the cultivation of the virus of fowl-pox | |
Howitt | Poliomyelitis Virus. Results of Treating with Certain Chemicals and with Heat. | |
Beadle et al. | Carbon dioxide narcosis | |
DE2050945A1 (en) | Process for growing viable Staphylococcus bacteria to produce an antiviral substance | |
Nelson | The stability of variola virus propagated in embryonated eggs | |
Cox et al. | Cultivation of vesicular stomatitis virus | |
Vogel et al. | The action of miracil in Schistosoma japonicum infections in laboratory animals | |
Rao et al. | ANIMAL. RH|| NOSPORIDIOSIS| N|| ND| A WITH (CASE REPORTS | |
Frenkel et al. | Cultivation of foot-and-mouth disease virus in explanted epithelial tissue of the bovine rumen | |
US4085206A (en) | Composition for treatment of infectious diseases in animals | |
Banting | Resistance to experimental cancer | |
Veerkamp et al. | Mode of action of beryllium on alkaline phosphatase | |
DE1030516B (en) | Nutrient soil for virus breeding | |
Ide et al. | Studies with a rhinovirus of bovine origin: I. growth in vitro of strain RS 3x | |
Verlinde et al. | Studies on haemagglutination by the EMC-MM-Columbia SK-group of viruses: IV. Experiments with egg-adapted virus | |
DE2524822C3 (en) | Neutral protease, process for its preparation and its use for disrupting animal tissue and for suspension cell culture |